John Parkinson

Athersys has developed its MultiStem cell therapy for COVID-19 Acute respiratory distress syndrome (ARDS). Athersys CEO Gil Van Bokkelen, PhD, and CFO Ivor Macleod, recently spoke to Contagion providing background on the company and their MultiStem therapy.

RECOVERY trial reported hospitalized COVID-19 patients did not see a benefit compared to those patients who received usual care.

The President gave Regeneron’s therapy, REGN-COV2, a ringing endorsement Wednesday night and stated both companies’ therapies should be given for free to the public.

This further emphasizes the higher rate of mortality in COVID-19 compared to influenza.

Within NIH is the National Center for Advancing Translational Sciences (NCATS) and they will oversee the grant awards. Christopher Austin, MD, director, NCATS, discusses the specifics of the 2 trials being expanded.

Aethlon Medical is developing its proprietary Hemopurifier, which is a therapeutic device designed for the single use depletion of circulating viruses.

A study found that 14% of them experienced cardiac arrest within two weeks of being admitted to the ICU.

Principal investigator Richard Becker, MD, director of the University of Cincinnati Heart, Lung and Vascular Institute discusses the phase 2 clinical trial for razuprotafib.

Regeneron’s REGN-COV2 reduced the time to alleviate symptoms.

In a national survey, parents responded they would not be getting a vaccine for their kids during the COVID-19 pandemic.

Apeiron Biologics reports on a case study related to COVID-19 related pneumonia.

Novavax made the announcement late yesterday about their investigational vaccine, NVX-CoV2373.

The Chinese government approves trial for Sinovac's vaccine in these patient populations.

In the second survey in a series, more respondents said they were wearing face coverings, less would get vaccinated, and there was a slight increase in their fears about the severity of the disease.

A small study is reporting very few adverse effects and low rates of COVID-19 transmission rates from mother to baby.

Medication shown to inhibit virus from infecting cells and replicating.

A pediatric cardiologist discusses the specifics of a case study, the importance of adaptability, and how her healthcare system has developed treatment protocols in these cases.

Scans typically used to diagnose strokes are showing physical signs in the lungs that identify COVID-19.

Eli Lilly’s investigational therapy, LY-CoV555, was shown to be well-tolerated and met its primary endpoint for one of its doses.

A survey from The Ohio State University shows a majority of Americans would get an approved vaccine.

In a newly published paper, investigators believe the novel virus will follow similar patterns to seasonal viruses like influenza.

An examination of ventilator patients found a significant number of them could suffer from a variety of life-long injuries.

A clinical-stage immunology company has an investigational therapy looking to target the tumor necrosis factor cytokine.

The investigational vaccine was regarded as well-tolerated and elicited an immune response.

An examination of a patient presenting with the condition in the early days of the pandemic without the access to current care protocols.

This test simultaneously detects and differentiates between SARS-CoV-2, influenza A and B.

If phase 1/2 data is positive, the companies plan to move into phase 3 by December.

The federal agency sent a checklist and priority list to all 50 states and 5 large American cities as it prepares for vaccine approval.

The test designed to detect SARS-CoV-2 will be available in Europe later this month and provides results in 15 minutes.

The company is recruiting up to 30000 Americans for AZD1222, its vaccine candidate, as it enters a late-stage trial.